Literature DB >> 16413842

Effective use of hormonal contraceptives: Part I: Combined oral contraceptive pills.

Kathryn M Curtis1, Camaryn E Chrisman, Anshu P Mohllajee, Herbert B Peterson.   

Abstract

This systematic review examines evidence regarding when during the menstrual cycle a woman can initiate combined oral contraceptive (COC) use and what can be done if a woman misses COCs. We searched the MEDLINE and EMBASE databases for articles published from 1966 to March 2005 related to COC initiation and to the effects of late or missed COCs. We identified 11 studies related to COC initiation and 25 studies related to the effects of missed pills. Evidence from these studies suggested that taking hormonally active pills for 7 consecutive days prevents normal ovulation and that initiating COCs through Day 5 of the menstrual cycle suppresses follicular activity. Studies on the effects of missed COCs generally showed that the risk of ovulation is greatest when the pill-free interval lasts >7 days. Limitations of this body of evidence include small sample sizes that may not reflect variation in larger populations, lack of a standard measurement of ovulation and difficulty in discerning how ovulation resulting from late or missed COCs corresponds to the risk of conception.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16413842     DOI: 10.1016/j.contraception.2005.08.003

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Population-level impact of hormonal contraception on incidence of HIV infection and pregnancy in women in Durban, South Africa.

Authors:  Gita Ramjee; Handan Wand
Journal:  Bull World Health Organ       Date:  2012-07-16       Impact factor: 9.408

2.  Event-Related Potentials in Women on the Pill: Neural Correlates of Positive and Erotic Stimulus Processing in Oral Contraceptive Users.

Authors:  Norina M Schmidt; Juergen Hennig; Aisha J L Munk
Journal:  Front Neurosci       Date:  2022-01-04       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.